Global Desloratadine Sales Market Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Desloratadine Sales Market Report 2024
Market Analysis and InsightsGlobal Desloratadine Market
Desloratadine is an antihistamine that is used to get relieve from allergic symptoms, such as sneezing, runny nose, and rashes due to chronic reactions.
Due to the COVID-19 pandemic, the global Desloratadine market size is estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Tablets accounting for % of the Desloratadine global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospitals segment is altered to an % CAGR throughout this forecast period.
The United States Desloratadine market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Desloratadine include Merck, Mylan, Lupin Pharmaceuticals, Sun Pharmaceutical, Dr.Reddy's, Guagndong Jiuming, Hainan Poly Pharm and Chengdu Mingri, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Desloratadine Scope and Market Size
The global Desloratadine market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Desloratadine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
Tablets
Injection
Hospitals
Clinics
Others
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
Merck
Mylan
Lupin Pharmaceuticals
Sun Pharmaceutical
Dr.Reddy's
Guagndong Jiuming
Hainan Poly Pharm
Chengdu Mingri
Desloratadine is an antihistamine that is used to get relieve from allergic symptoms, such as sneezing, runny nose, and rashes due to chronic reactions.
Due to the COVID-19 pandemic, the global Desloratadine market size is estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Tablets accounting for % of the Desloratadine global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospitals segment is altered to an % CAGR throughout this forecast period.
The United States Desloratadine market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Desloratadine include Merck, Mylan, Lupin Pharmaceuticals, Sun Pharmaceutical, Dr.Reddy's, Guagndong Jiuming, Hainan Poly Pharm and Chengdu Mingri, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Desloratadine Scope and Market Size
The global Desloratadine market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Desloratadine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
Tablets
Injection
Segment by Application
Hospitals
Clinics
Others
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Merck
Mylan
Lupin Pharmaceuticals
Sun Pharmaceutical
Dr.Reddy's
Guagndong Jiuming
Hainan Poly Pharm
Chengdu Mingri